Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment

NCT01934465 · clinicaltrials.gov ↗
COMPLETED
Status
300
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Hellenic Oncology Research Group